General Information of Drug (ID: DMK91WR)

Drug Name
MP-136 Drug Info
Indication
Disease Entry ICD 11 Status REF
Lipid metabolism disorder 5C52.Z Discontinued in Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMK91WR

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lobeglitazone DMHY3IP Type-2 diabetes 5A11 Approved [3]
Fenofibrate DMFKXDY Coronary atherosclerosis Approved [4]
Bezafibrate DMZDCS0 Hypercholesterolaemia 5C80.0 Approved [5]
Ciprofibrate DMGC5DB Hyperlipoproteinemia 5C80 Approved [4]
Pemafibrate DMD1VZL Hyperlipidemia 5C80.Z Approved [6]
MURAGLITAZAR DMG3NFZ N. A. N. A. Phase 3 [7]
Ragaglitazar DMFSHEM Type-1 diabetes 5A10 Phase 3 [8]
CS-038 DM67P0F Type-2 diabetes 5A11 Phase 3 [9]
TESAGLITAZAR DMGRBN5 Type-1 diabetes 5A10 Phase 3 [10]
GFT-505 DM7ZOAE Non-alcoholic steatohepatitis DB92.1 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Peroxisome proliferator-activated receptor alpha (PPARA) TTJ584C PPARA_HUMAN Agonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031057)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 593).
3 Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
4 Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
5 Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92.
6 Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810.
7 Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
8 Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
9 Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
10 Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.
11 Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.